open access

Vol 49, No 4 (2011)
REVIEW
Published online: 2012-01-16
Submitted: 2012-01-16
Get Citation

Digital pathology in personalized cancer therapy

Janina Słodkowska, Marcial Garcia Rojo
DOI: 10.5603/FHC.2011.0080
·
Folia Histochem Cytobiol 2011;49(4):570-578.

open access

Vol 49, No 4 (2011)
REVIEW
Published online: 2012-01-16
Submitted: 2012-01-16

Abstract

The development of small molecule inhibitors of growth factor receptors, and the discovery of somatic mutations of the thyrosine kinase domain, have resulted in new paradigms for cancer therapy. Digital microscopy is an important tool for surgical pathologists. The achievements in the digital pathology field have modified the workflow of pathomorphology labs, enhanced the pathologist’s role in diagnostics, and increased their contribution to personalized targeted medicine. Digital image analysis is now available in a variety of platforms to improve quantification performance of diagnostic pathology. We here describe the state of digital microscopy as it applies to the field of quantitative immunohistochemistry of biomarkers related to the clinical personalized targeted therapy of breast cancer, non-small lung cancer and colorectal cancer: HER-2, EGFR, KRAS and BRAF genes. The information is derived from the experience of the authors and a review of the literature. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 570–578)

Abstract

The development of small molecule inhibitors of growth factor receptors, and the discovery of somatic mutations of the thyrosine kinase domain, have resulted in new paradigms for cancer therapy. Digital microscopy is an important tool for surgical pathologists. The achievements in the digital pathology field have modified the workflow of pathomorphology labs, enhanced the pathologist’s role in diagnostics, and increased their contribution to personalized targeted medicine. Digital image analysis is now available in a variety of platforms to improve quantification performance of diagnostic pathology. We here describe the state of digital microscopy as it applies to the field of quantitative immunohistochemistry of biomarkers related to the clinical personalized targeted therapy of breast cancer, non-small lung cancer and colorectal cancer: HER-2, EGFR, KRAS and BRAF genes. The information is derived from the experience of the authors and a review of the literature. (Folia Histochemica et Cytobiologica 2011; Vol. 49, No. 4, pp. 570–578)
Get Citation

Keywords

digital pathology; immunohistochemistry; IHC biomarkers; breast cancer; NSCLC; personalized targeted therapy; EGFR; HER-2; telepathology systems; quantitative analysis

About this article
Title

Digital pathology in personalized cancer therapy

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 49, No 4 (2011)

Pages

570-578

Published online

2012-01-16

DOI

10.5603/FHC.2011.0080

Bibliographic record

Folia Histochem Cytobiol 2011;49(4):570-578.

Keywords

digital pathology
immunohistochemistry
IHC biomarkers
breast cancer
NSCLC
personalized targeted therapy
EGFR
HER-2
telepathology systems
quantitative analysis

Authors

Janina Słodkowska
Marcial Garcia Rojo

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl